Oroxcell is a drug discovery and development company identifying new generation of chemical entities dedicated to pain treatment.
Primary clinical indications of Oroxcell compounds are visceral, chronic, neuropathic and osteoarthritic pain. ORC056, lead candidate, shows an excellent safety profile and a strong analgesic effect in all animal models tested. The compounds benefit from a strong IP and have low cost of synthesis (5 chemical steps). Oroxcell is looking for 1.5 M€ to pursue preclinical development of ORC056 up to an indentified deal with a major Pharma leader.